Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.82 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | BCL6 | P41182 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorazanil SCHEMBL29652081 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| Chlorazanil SCHEMBL22207597 | 0.98 | ADORA3 (0.97) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| SCHEMBL14214597 | 0.91 | SCN9A (1.00) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| SCHEMBL21496119 | 0.85 | SMN1; SMN2 (0.74) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| Chlorazanil SCHEMBL28051331 | 0.85 | KDR (0.72) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| SCHEMBL8236544 | 0.82 | SMN1; SMN2 (1.00) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| SCHEMBL2494840 | 0.82 | RAB9A (1.00) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| SCHEMBL2352230 | 0.81 | ADORA3 (0.69) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| Amanozine SCHEMBL689928 | 0.81 | BCL6 (1.00) | ADORA3SLC6A2PDE4AKDRSCN9A | |
| Amanozine SCHEMBL30264199 | 0.81 | BCL6 (1.00) | ADORA3SLC6A2PDE4AKDRSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| CN-107022268-A | A kind of cable water mildow-proof inhibition renovation agent and preparation method thereof | 段辉 | 2017-08-08 | — | — | CN | claimed |
| US-9511139-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| EP-3072526-A1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | Oncomed Pharmaceuticals, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| EP-2488204-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2016-04-06 | — | — | EP | claimed |
| US-20150118232-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2015-04-30 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-1009400-B1 | COMBINATION THERAPY COMPRISING ATORVASTATIN AND AN ANTIHYPERTENSIVE AGENT | PFIZER (US) | 2004-12-29 | — | — | EP | claimed |
| EP-1087953-B1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX SA (FR) | 2004-11-17 | — | — | EP | claimed |
| WO-2004075857-A2 | COMPOSITIONS, COMBINATIONS, AND METHODS FOR TREATING CARDIOVASCULAR CONDITIONS AND OTHER ASSOCIATED CONDITIONS | PHARMACIA CORPORATION (US) | 2004-09-10 | — | — | WO | claimed |
| CN-1473567-A | Combined therapeutic method including acrivastine and antihypertensive | ������ҩ������˾ | 2004-02-11 | — | — | CN | claimed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | ADORA3 2358/4885SLC6A2 277/4885PDE4A 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.